|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas.
|
1742726 |
1991 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
None of eight SCCs in situ and none of eight actinic keratoses expressed bcl-2.Sixteen of 18 MMs expressed bcl-2.
|
7632062 |
1995 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although bcl-2 immunoreactivity was observed in all levels of primary cutaneous malignant melanomas, in 43% (9/21) of deep melanomas (Clark level > or = III), and 100% (7/7) of thick tumors (thickness > or = 4.00 mm), there was focal loss of immunoreactivity.
|
7777475 |
1995 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bcl-2 strongly decorated the tumor cells in all 14 cases of primary MM (80%, 2-4+); in the five in situ MM, bcl-2 stained the atypical melanocytes at the dermal-epidermal junction (DEJ) and throughout the epidermis (75%, 1-2+).
|
8599446 |
1995 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that altered expression of bcl-2 is common in uveal melanomas and is not related to histologic grade.
|
8639055 |
1996 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This is different from malignant melanomas in which bcl-2 expression is reduced as compared to normal melanocytes.
|
8721444 |
1996 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 expression in malignant melanoma and its prognostic significance.
|
8783649 |
1996 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.
|
9461199 |
1998 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The increase in Bcl-2 expression mediated by mutated ras therefore qualifies as a rational explanation for the enhanced chemoresistance of human melanoma expressing mutated N-Ras.
|
10504052 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Twenty cases of malignant melanoma arising from pre-existing nevi were selected and studied by immunohistochemistry for the expression of p53 (D07) CDK4I/MTS-1/INK <4, which detects both wild and mutant type, p16 CDK4I/MTS-1/INK <4, and Bcl-2 using an avidin-biotin technique on formalin-fixed, paraffin-embedded sections.
|
10575157 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This phase I-II clinical study investigated the combination of BCL2 ASO (augmerosen, Genasense, G3139) and dacarbazine in patients with advanced malignant melanoma expressing BCL2.
|
11095261 |
2000 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A mitochondrial pathway was involved in melanoma apop tosis, as indicated by altered mitochondrial membrane potential (delta psi(m)) and down-regulation of Bcl-2 protein level after iNOS inhibition.
|
11196180 |
2001 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To further demonstrate the importance of bcl-2 and validate the related antiapoptotic protein bcl-xL as targets for antisense therapy in melanoma, their implication as survival factors in melanoma cells of different clinical stages as well as in normal melanocytes was investigated.
|
11874491 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-x(L) is an antiapoptotic member of the Bcl-2 family and is universally expressed in human melanoma.
|
11948488 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes.
|
11959101 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes.
|
11959101 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
This linkage helps explain the vital roles of both Mitf and Bcl2 in the melanocyte lineage and the well-known treatment resistance of melanoma.
|
12086670 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This linkage helps explain the vital roles of both Mitf and Bcl2 in the melanocyte lineage and the well-known treatment resistance of melanoma.
|
12086670 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together our results indicate that bcl-2 plays an important role in melanoma angiogenesis, and that VEGF mRNA stabilization and HIF-1-mediated transcriptional activity are two important control points in bcl-2/hypoxia-induced VEGF expression.
|
12205045 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, in contrast to SK, SM, MN, and MM coexpression of bcl-2 and c-myc was found more frequently in MMET (PCR 25/30, p < 0.01, IH 19/34, p < 0.01).
|
12449722 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antisense therapy against the Mcl-1 gene product, possibly in combination with antisense strategies targeting other antiapoptotic Bcl-2 family members, appears to be a rational and promising approach to help overcome treatment resistance of malignant melanoma.
|
12787138 |
2003 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Roughly one-third of the data suggests an increase in Bcl-2 expression with advancing melanoma, while another third suggests a decrease.
|
14598887 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings confirm that bcl-2 plays a crucial role in melanoma angiogenesis and demonstrate for the first time that downregulation of bcl-2 by antisense treatment has potential to inhibit angiogenesis independent of its effect on cell survival.
|
14627985 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, antisense to Bcl-2 comprises a most promising therapy and is being tested in combination with anticancer drugs in randomized phase III trials for chronic lymphocytic leukemia, multiple myeloma, and malignant melanoma.
|
14654935 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor.
|
14660675 |
2004 |